Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 2
1952 1
1954 2
1957 3
1959 2
1960 3
1964 1
1965 5
1966 1
1968 1
1969 1
1970 1
1971 1
1972 1
1973 2
1975 1
1976 1
1978 2
1980 1
1981 1
1982 2
2004 1
2006 2
2007 1
2011 1
2012 2
2013 5
2014 2
2015 3
2016 6
2017 2
2018 2
2019 9
2020 6
2021 8
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Middleton PG, et al. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. N Engl J Med. 2019. PMID: 31697873 Free PMC article. Clinical Trial.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group. Keating D, et al. N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18. N Engl J Med. 2018. PMID: 30334692 Free PMC article. Clinical Trial.
Asthma and coagulation.
de Boer JD, Majoor CJ, van 't Veer C, Bel EH, van der Poll T. de Boer JD, et al. Among authors: majoor cj. Blood. 2012 Apr 5;119(14):3236-44. doi: 10.1182/blood-2011-11-391532. Epub 2012 Jan 18. Blood. 2012. PMID: 22262775 Free article. Review.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.
Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients.
Kos R, Brinkman P, Neerincx AH, Paff T, Gerritsen MG, Lammers A, Kraneveld AD, Heijerman HGM, Janssens HM, Davies JC, Majoor CJ, Weersink EJ, Sterk PJ, Haarman EG, Bos LD, Maitland-van der Zee AH; Amsterdam Mucociliary Clearance Disease (AMCD) Research Group and the Amsterdam UMC Breath Research Group. Kos R, et al. Among authors: majoor cj. J Cyst Fibros. 2022 Jan;21(1):e28-e34. doi: 10.1016/j.jcf.2021.04.015. Epub 2021 May 18. J Cyst Fibros. 2022. PMID: 34016557 Free article. Review.
Tobramycin and vestibulotoxicity: retrospective analysis of four cases.
Vonk SEM, Weersink EJM, Majoor CJ, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) Research Group. Vonk SEM, et al. Among authors: majoor cj. Eur J Hosp Pharm. 2022 Mar;29(e1):e88-e90. doi: 10.1136/ejhpharm-2020-002588. Epub 2021 Mar 22. Eur J Hosp Pharm. 2022. PMID: 33753422 Free PMC article.
Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial.
de Boer JD, Berger M, Majoor CJ, Kager LM, Meijers JC, Terpstra S, Nieuwland R, Boing AN, Lutter R, Wouters D, van Mierlo GJ, Zeerleder SS, Bel EH, van't Veer C, de Vos AF, van der Zee JS, van der Poll T. de Boer JD, et al. Among authors: majoor cj. Eur Respir J. 2015 Dec;46(6):1636-44. doi: 10.1183/13993003.00459-2015. Epub 2015 Sep 17. Eur Respir J. 2015. PMID: 26381519 Free article. Clinical Trial.
Heparin and osteoporosis.
Majoor CL. Majoor CL. Lancet. 1965 Sep 25;2(7413):641. doi: 10.1016/s0140-6736(65)90556-8. Lancet. 1965. PMID: 4157574 No abstract available.
87 results